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Abstract: We present two rare cases of in situ mantle cell lymphoma (“in situ MCL”) and three cases of MCL with
mantle zone growth pattern (MCL-MZGP). The patients include four males and one female, with a median age of
66 years (range, 52 to 86 years). Two present with isolated lymphadenopathy and three with multiple lymphadenopathy. At presentation, the complete blood count (CBC) and serum lactate dehydrogenase (LDH) are normal in
all cases. Histologic examination reveals an in situ pattern in two cases and a mantle zone growth pattern in three
cases. The staging bone marrow biopsies show minimal involvement by lymphoma in one case and no morphologic
evidence of lymphoma in four cases. All cases are positive for cyclin D1, including two with typical MCL phenotype
and three with CD5-negativity. Four out of five cases express kappa light chain. FISH study for t(11;14) is performed
in three cases, of which one is positive and two are inconclusive. For four patients with a median follow-up of 38
months, three are in clinical remission and one has persistent disease. In conclusion, the “in situ MCL” is associated with incidental finding, indolent clinical course and lower tumor burden. The predominant usage of kappa light
chain and frequent CD5-negativity observed in our cases are unusual. We review the clinical and laboratory features
of “in situ MCL” cases in the literature.
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Introduction
Mantle cell lymphoma (MCL) comprises 3 to
10% of non-Hodgkin lymphomas and has an
aggressive clinical course with a median survival of 3 to 5 years [1]. MCL is characterized by
t(11;14)(q13;q32) translocation involving the
CCND1 and immunoglobulin heavy chain
genes. This translocation results in overexpression of cyclin D1, which leads to dysregulation
of the cell cycle and, combined with chromosomal instability and activation of cell survival
mechanisms, contributes to the pathogenesis
of MCL [2, 4]. MCL typically co-expresses B-cell
antigens (CD19 and CD20) and CD5 and lacks
CD23, with lambda light chain being more commonly used than kappa light chain. Three histological patterns have been recognized in lymphoid tissues: mantle zone, nodular and diffuse. It is believed that the histological patterns
reflect the natural process of disease progression. A larger minority of MCL shows mantle

zone pattern that appears to be associated
with a better prognosis [3]. On very rare occasions, cyclin D1-positive cells are restricted to
the mantle zones in a morphologically inconspicuous lymph node. This histologic pattern
has been designated as “in situ MCL”, which is
often an incidental finding and associated with
indolent clinical behavior [12]. “In situ MCL” is
considered as a very early stage of MCL or even
a preneoplastic state. Due to its low frequency,
the biological behaviors and clinical implications of “in situ MCL” remain unclear. Here, we
present the clinicopathological features of five
cases of MCL with in situ or MZGP pattern and
also review the literature on “in situ MCL”.
Materials and methods
Case selection
We identify five cases of MCL with either “in situ
MCL” or MCL-MZGP diagnosed in two tertiary
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hospitals of the North Shore-Long Island Jewish
Health System from 2008 to 2013. All cases
are identified on the basis of the histologic and
immunophenotypic features.
Histological and immunohistochemical studies
Paraffin-embedded tissue is available from the
diagnostic biopsies. Immunohistochemical studies are performed with a panel of pre-diluted
antibodies including CD20 (Ventana), CD3 (Ventana), Cyclin D1 (Dako), CD5 (Ventana), CD10
(Ventana), CD23 (Ventana), BCL-6 (Dako) and
BCL-2 (Zymed). Staining is performed using
automated immunostainer (Ventana Medical
System, Tucson, AZ, USA).
Flow cytometric analysis
Cells are stained with a panel of fluorescence
labeled monoclonal antibodies including CD3,
CD4, CD5, CD7, CD8, CD10, CD19, CD20,
CD23, FMC7, kappa and lambda. The cells are
washed with PBS for three times and fixed in
4% paraformadehyde PBS solution before analysis. Routine three-color flow cytometric analysis is performed using FACSDiva software
(Becton-Dickenson Biosciences, San Jose, California).
Fluorescence in situ hybridization study
Fluorescence in situ hybridization (FISH) analysis is performed on tissue imprints using both
LSI IGH/CCND1 dual-color, dual-fusion translocation probe and LSI IGH dual-color, breakapart probe (Abbott Molecular, Des Plains, IL)
following the standard protocol.
Immunoglobulin variable gene analysis
Genomic DNA is extracted from formalin-fixed
and paraffin embedded tissue sections (QIAGEN GmbH, Hilden, Germany). PCR is performed on the genomic DNAs using 5’ Ig heavy
chain variable region leader primer and 3’ constant region primer. The PCR products are used
for IGHV gene mutation analysis.
Results
Clinical features
Table 1 summarizes the clinical and laboratory
features of the five cases. The patients include
four males and one female, with a median age
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of 66 years (range, 52 to 86 years). Clinical history is remarkable for carcinoma in two patients
and non-caseating granuloma in one patient.
The remaining two patients have no significant
past history. Two patients present with isolated
lymphadenopathy and three with multiple
lymphadenopathy. At presentation, the CBC
and serum LDH are normal in all cases. There is
no evidence of splenic or gastrointestinal system involvement. The staging bone marrow
biopsies show minimal involvement in one
case, whereas no evidence of lymphoma is
observed by morphology and cyclin D1 staining
in the remaining cases. However, a minute
monoclonal B-cell population is identified by
flow cytometry in three of the last four cases.
Four patients receive chemotherapy and one
patient is newly diagnosed. The four patients
who received treatment are still alive after a
median follow-up of 38 months (range, 34 to
48 months), with three in clinical remission and
one with persistent disease.
Histopathology and immunohistochemical
studies
“In situ MCL”: In case 1 the lymph node is mostly replaced by non-necrotizing granulomas and
only scattered lymphoid follicles, some containing reactive germinal centers, and small areas
of T-zones are identified between the granulomas (Figure 1A). In case 2 the lymph node
biopsy shows architecture preservation with
prominent paracortical hyperplasia, some follicles with reactive germinal centers, and presence of sinuses (Figure 1B). In both cases, the
mantle zones appear normal or only mildly
expanded (Figure 1C and 1D). There is no definitive morphologic evidence of lymphoproliferative disorder. However, flow cytometry performed as part of routine lymphoma work up
identify a monoclonal B-cell population in both
cases.
Immunohistochemical studies are subsequently performed on paraffin-embedded tissue sections. The germinal center cells show positive
staining for CD20, BCL-6, and are negative for
BCL-2. The mantle zone cells show positive
staining for CD20, BCL-2 and cyclin D1 (Figure
1E), and are negative for CD5 (Figure 1F). The
cyclin D1-positive cells are confined to the mantle zones without mantle zone expansion.
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Table 1. Clinical and laboratory features of five cases of MCL
Cases
Age
Sex
Clinical history
CBC
WBC (X109/L)
Hb (g/dL)
Plt (X109/L)
LDH
Lymphadenopathy
Splenomegaly
Site of Bx
Histology
In situ MCL
MCL-MZGP
BM involvement
Immunophenotype
Surface Igs
CD19
CD20
CD5
CD23
CD38
FMC-7
cyclin D1
FISH for t(11;14)
IGHV mutation
Treatment
Follow-up
Status

No. 1
65
Female
Granuloma

No. 2
52
Male
Vocal SCC

No. 3
86
Male
Cancer

No. 4
67
Male
No

No. 5
46
Male
No

6.3
13.5
219
146
Single
No
Cervical LN

9.0
15.5
188
200
Single
No
Cervical LN

5.6
15.3
248
189
Multiple
No
Cervical LN

6.9
14.5
247
196
Multiple
No
Axillary LN

6.4
15.2
198
214
Multiple
No
Axillary LN

Yes

Yes

Minimal

No

Yes
Yes
No

Yes
No*

Yes
No*

kappa
+
+
+ (partial)
+
+ (partial)
+

Kappa
+
+
N/A
+
+

#

#

Yes
Yes
38
AND

N/A
Yes
38
AND

Kappa
+
+
+
+
+
+
N/A
N/A
No
2
Alive

Kappa
+
+
+
N/A
+
+
N/A
Yes
48
AWD

lambda
+
+
+
+
N/A
+
N/A
N/A
Yes
34
AND

*

AND, alive without disease; AWD, alive with disease; Bx, biopsy; BM, bone marrow; FISH, fluorescence in situ hybridization; Hb,
hemoglobin; Ig, immunoglobulin; IGHV, Ig heavy chain variable region; LN, lymph node; N/A, not applicable; Plt, platelet; SCC,
squamous cell carcinoma; WBC, white blood cell. *No involvement by morphology and cyclin D1 staining, but flow cytometry
shows a minute population of monoclonal B-cells. #In conclusive due to limited number of cells for analysis.

MCL-MZGP: In case 4 and 5, the lymph nodes
are partially effaced by crowded follicles containing reactive germinal centers. The mantle
zones are markedly expanded and focally fused
between adjacent follicles. Occasional primary
follicles are also noted. T-zones are present and
sinuses are intact in some areas (Figure 2A, 2B
and 2E).
Immunohistochemical studies are performed
on paraffin-embedded tissue sections. The
mantle zone cells reveal positive staining for
CD20 and cyclin D1, and are negative for CD10
and CD23. The neoplastic cells appear to be
CD5 positive in case 5, but are negative in case
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4. The mantle zones are virtually replaced by
cyclin D1 positive cells which focally extend into
interfollicular regions (Figure 2C, 2D and 2F).
The germinal centers appear positive for CD20,
CD10 and bcl-6, and negative for bcl-2. The
interfollicular regions comprise of predominantly T-cells.
Mixed “in situ” and MZGP pattern: In case 3,
some follicles have normal mantle zones consistent with in situ pattern whereas others
show mantle zone expansion consistent with
MZGP pattern (Figure 3A). The mantle zone
cells show positive staining for CD20, CD5 and
cyclin D1 (Figure 3B-D), and are negative for
CD10 and CD23.
Int J Clin Exp Pathol 2014;7(3):1042-1050
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Figure 1. “In situ MCL” in lymph nodes. (A) H&E staining in case 1 reveals a reactive-appearing follicle with germinal
center in a background of non-caseating granulomas (X100). (B) H&E staining in case 2 reveals a lymph node with
multiple reactive-appearing follicles and prominent paracortical hyperplasia (X20). H&E higher power view of two
reactive-appearing follicles with germinal centers and normal mantle zones (X200, C) and (X400, D). (E) Immunohistochemical staining for cyclin D1 highlights scattered positive cells in mantle zones (X200). (F) CD5 (case 2) reveals
negative staining in mantle zone cells and numerous T-cells in paracortical regions (X200).

Flow cytometry findings
In all the cases flow cytometric analysis is performed in both lymph node and bone marrow
specimens (Table 1). Two cases show classic
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MCL phenotype, whereas three cases are CD5negative, including both “in situ MCL” cases.
Interestingly, four out of five cases express
kappa light chain. Both CD38 and FMC-7 are
positive in all the cases with data available for

Int J Clin Exp Pathol 2014;7(3):1042-1050
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Figure 2. MCL-MZGP in lymph nodes. H&E staining in case 5 (A, X20) and case 4 (B, X40) reveals numerous reactiveappearing follicles with germinal centers and focally intact sinuses. Immunohistochemical staining for cyclin D1
highlight expanded mantle zones in case 5 (C) and case 4 (D) (X40). (E) Higher power view of one reactive-appearing
follicle with germinal centers and expanded mantle zones (H&E, X200). (F) Higher power view of cyclin D1 staining
in one follicle (X200).

analysis. CD23 is partially expressed in one
case.
FISH study and IGHV gene mutation analysis
In three cases we study the t(11;14) translocation by FISH using both dual-color, dual-fusion
translocation probe and dual-color break-apart
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probe, of which one is positive, and two are
inconclusive due to limited number of cells for
analysis and both are “in situ MCL”. In addition,
we have sufficient material to perform IGHV
study using paraffin embedded sections in
case 1, which shows a clonal B-cell population
with evidence of somatic mutation of IGHV
gene.
Int J Clin Exp Pathol 2014;7(3):1042-1050
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Figure 3. Histopathology and immunohistochemical studies in case 3. (A) H&E staining reveals numerous reactiveappearing follicles (X40). (B) immunohistochemical staining for cyclin D1 reveals a mixture of MCL-MZGP and “in situ
MCL” (X40). Higher power view of Cyclin D1 staining for “in situ MCL” (C) and MCL-MZGP (D) (X200).

Discussion
“In situ MCL” is very rare and only a small number of cases have been reported in literature
[4-12]. A recent study that evaluates 1292 consecutive reactive lymph nodes from 131
patients reveals no single case of “in situ MCL”
[13]. Given its rarity, the biological behaviors
and clinical implication of “in situ MCL” remain
unclear. Two cases reported here show an in
situ pattern in an otherwise reactive lymph
node and are both incidental findings and have
indolent clinical course, which fulfill the diagnostic criteria for “in situ MCL”. On the other
hand, MCL-MZGP appears to have higher tumor
burden at presentation than “in situ MCL”.
However, we do not observe any difference
between the two groups with regard to overall
survival. All four patients who receive treatment
are still alive at the time of this submission, but
one patient with MCL-MZGP has persistent disease. Whether “in situ MCL” represents a pre-
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cursor lesion or early colonization by MCL is still
being debated. Studies have shown that
patients with an incidentally diagnosed “in situ
MCL” do not progress to overt disease, irrespective of whether treatment has been administrated or not. Furthermore, in some cases “in
situ MCL” is retrospectively identified years
before the discovery of overt MCL [12, 14].
Interestingly, our case 3 shows a mixture of in
situ pattern and mantle zone growth pattern in
a single lymph node, which illustrates the disease progression. These findings support the
notion that “in situ MCL” may represent a precursor or even a preneoplastic lesion. On the
other hand, in situ lesions have also been identified in some patients with a previous history
of MCL who develop overt MCL soon after the
discovery of in situ lesion. One study suggests
that these cases should be considered as early
colonization by MCL rather than a precursor
lesion [13]. It is important to make such a distinction because the managements for these
two groups are different.
Int J Clin Exp Pathol 2014;7(3):1042-1050
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Table 2. Clinical and laboratory features of twenty-one reported in situ MCL cases
Case

Age/
Sex

1

29/F

Inguinal LN

LNs

Yes

Yes

W&W

19.5

AWD

-

-

-

2

72/F

Submandibular LN

No

Yes

Yes

W&W

12

AWD

-

-

Granuloma

3

42/F

Cervical LN

No

No

No

W&W

1

AND

-

-

Breast Ca

4

84/F

Spleen

No

N/A

No

W&W

1.4

Died

-

FL

Colon Ca

5

42/M

Supclaviculal LN

No

No

N/A

RT

1.7

AND

-

-

Castleman disease

6

59/M

Cervical LN

No

No

No

W&W

5

AND

-

-

Thyroid ca

Site of Bx

Other
F/U
Comosite
BM PB Management
Status CD5
sites
(yr)
lymphoma

Other
pathology

7

65/F

LN

No

Yes N/A

Chemo

0.5

AND

-

-

Granuloma

8

40/M

Cervical LN

No

N/A N/A

N/A

N/A

N/A

-

FL

-

9

70/M

Cervical LN

No

N/A

No

W&W

4

MCL

-

-

-

10

70/F

Nasopharynx

No

No

No

W&W

3

AND

+

-

-

11

58/M

Intestine

No

Yes

No

Chemo

1.4

AND

+

-

-

12

42/F

LNs, GIT

LNs

Yes

No

Chemo

6

AND

+

-

-

13

78/F

Lacrimal gland

No

No

No

N/A

N/A

N/A

+

eMZL

-

14

72/F

Cervical

No

N/A

No

RT

2

AND

+

NMZL

Breast Ca

15

82/M

Oropharynx

LT

N/A Yes

W&W

3

AWD

+

CLL/SLL

-

16

82/M

LN

No

No

No

Chemo

1.5

AND

+

CLL/SLL

-

17

80/M

Inguinal LN

LNs

Yes

Yes

Chemo

N/A

N/A

+

CLL/SLL

-

18

80/M

Cervical LN

No

No

No

Chemo

1.5

Died

+

FL

-

19

65/F

Intramammal LN

LNs

No

No

Chemo

5

AND

+

FL

-

20

65/M

Appendix

No

N/A N/A

W&W

4

MCL

+

-

-

21

68/M

Mediastinal LN

No

N/A N/A

W&W

1

AND

N/A

-

-

AND, alive with no disease; AWD, alive with disease; Bx, biopsy; BM, bone marrow; Ca, carcinoma; Chemo, chemotherapy; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; eMZL, extranodal marginal zone lymphoma; F, female; FL, follicular lymphoma; F/U, follow up; GIT,
gastrointestinal; LN, lymph node; LT, lymphoid tissue; M, male; N/A, not applicable; NMZL, nodal marginal zone lymphoma; PB, peripheral blood; RT,
radiation therapy; W&W, watch and wait; yr, year.

In reviewing of the literature we identify twentyone “in situ MCL” cases (Table 2) [4-12]. The
clinical and laboratory features of the twentyone cases plus two current cases are reviewed.
The median age at presentation is 65 years
(range, 29 to 84 years), with no significant sex
predilection. Most patients are asymptomatic
and present with a single enlarged lymph node.
Extranodal involvement is observed in some
patients. Splenic involvement is very rare
though bone marrow or/and peripheral blood
involvement is observed in a subset of patients.
The in situ lesion is usually an incidental finding
and most patients are managed with a “watch
and wait” approach. The vast majority of
patients are alive without disease progression
after a median follow up of three years.
MCL is characteristically CD5-positive, but a
small subset has been reportedly CD5 negative, which appears to be associated with indolent clinical course and nodal involvement [15,
16]. Based on CD5 expression, twenty-two of
the twenty-three cases can be divided into two
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subgroups: (1) CD5 negative “in situ MCL”.
There are eleven patients with a male to female
ratio of 5 to 6. The median age is 59 years
(range, 29 to 84 years). Most patients (8 of 11
cases) have a clinical history of cancer or
inflammatory diseases. All but one patient have
nodal involvement. Four patients receive either
chemotherapy or radiation therapy. Three
cases with IGHV mutation status available for
analysis show evidence of somatic hypermutation. (2) CD5 positive “in situ MCL”. There are
eleven cases in this group as well, with a median age of 72 years (range, 42 to 82 years). The
male to female ratio is 6 to 5. Of the eleven
patients, six have extranodal involvement, four
have multiple lymphadenopathy, and seven are
associated with other low grade B-cell lymphomas. Seven out of ten patients receive treatments. In summary, it appears that CD5 negativity in “in situ MCL” is associated with younger
age, history of cancer or inflammatory diseases, nodal involvement, and lower chance to
receive treatment, whereas CD5 expression is
associated with older age, frequent extranodal
Int J Clin Exp Pathol 2014;7(3):1042-1050
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involvement, frequent association with other
low-grade B-cell lymphomas, and higher chance
to receive treatment. However, the two groups
do not show any difference in overall survival.
Proposed cells of origin for MCL include memory and naïve splenic marginal zone cells, peripheral memory B-cells, and lymphoid follicle mantle cells [17]. “In situ MCL” is believed to be
related to naïve cells of primary follicle cells
and of the inner mantle zone of the secondary
follicles. Gene expression analysis reveals that
MCL with high mutation rates in IGHV gene
demonstrates a gene signature similar to memory B-cells while MCL with low mutation rates
resembles naïve B-cells [18]. Three of the CD5negative MCL cases show somatic hypermutation, suggesting that at least a subset of “in situ
MCL” may originate from memory B-cells.
Further study may help our understanding of
the cell origin and pathogenesis of “in situ
MCL”.
MCL exhibits predominant expression of lambda light chain, which is different from other lymphomas. The IGHV gene repertoire in MCL is
remarkably biased, with four genes (IGHV3-21,
IGHV4-34, IGHV1-8, and IGHV3-23) collectively
accounting for almost half of the cases [19].
Immunogenetic studies have demonstrated the
following features in MCL: (i) remarkable biases
in the IGHV gene repertoire; (ii) restricted associations of certain V, D and J genes, leading to
the formation of stereotyped B-cell receptors
(BCRs); and (iii) very precisely targeted somatic
hypermutation (SHM). The bias is very pronounced among IGHV3-21 MCL cases that
almost exclusively express lambda light chains
and display highly restricted use of the IGLV319 gene. These findings suggest that an antigen-driven process may be implicated in the
pathogenesis of MCL, at least for subsets of
cases [20]. As opposed to lambda predominance seen in MCL, our cases show predominant usage of kappa light chain, which is also
observed in a small cohort of indolent leukemic
MCL [21]. All these cases appear to have a relatively indolent clinical course. Whether they
represent a distinct functional group is still
unclear at this time. Additional study is needed
to address this issue.
In summary, we add two cases to a rare collection of “in situ MCL” that is often incidental finding and associated with indolent clinical course.
1049

The kappa predominance and frequent CD5negativity observed in our cases are unusual
for MCL, which suggests a possible antigendriven origin in these cases. In reviewing of the
literature, we have shown that “in situ MCL”
appears to be heterogeneous.
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